$-0.20 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)

July 18, 2017 - By reb123z

 $ 0.20 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA)
Investors sentiment decreased to 1.29 in Q4 2016. Its down 1.10, from 2.39 in 2016Q3. It dived, as 12 investors sold Vanda Pharmaceuticals Inc. shares while 46 reduced holdings. 20 funds opened positions while 55 raised stakes. 39.66 million shares or 1.45% less from 40.25 million shares in 2016Q3 were reported.
Jpmorgan Chase And Com reported 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Alabama-based Weiss Multi has invested 0.04% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Savings Bank Of Montreal Can invested in 10,976 shares. Gemmer Asset Mngmt Limited Company reported 594 shares. Proshare Advisors Lc has invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Macquarie Grp Inc Limited stated it has 1.37M shares or 0.04% of all its holdings. Invesco Ltd reported 488,025 shares. Tower Cap Limited Liability (Trc) holds 945 shares or 0% of its portfolio. Blackrock Inc has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Point72 Asia (Hong Kong) Limited holds 0% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 216 shares. Millennium Mgmt Ltd owns 1.02 million shares for 0.03% of their portfolio. Blackrock Advisors Ltd Liability Corporation stated it has 98,236 shares. Susquehanna Intll Llp accumulated 100,912 shares. Old Mutual Global (Uk) invested in 0.01% or 52,372 shares. State Board Of Administration Of Florida Retirement Systems owns 107,768 shares or 0.01% of their US portfolio.

Analysts await Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings on July, 26. They expect $-0.20 earnings per share, down 400.00 % or $0.16 from last year’s $-0.04 per share. After $-0.17 actual earnings per share reported by Vanda Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 17.65 % negative EPS growth. The stock decreased 1.20% or $0.2 during the last trading session, reaching $16.4. About 272,514 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since July 18, 2016 and is uptrending. It has outperformed by 34.90% the S&P500.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 7 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Vanda Pharmaceuticals had 11 analyst reports since September 2, 2015 according to SRatingsIntel. The rating was initiated by Aegis Capital with “Buy” on Wednesday, November 9. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) earned “Buy” rating by Jefferies on Thursday, October 6. The firm has “Buy” rating given on Tuesday, June 27 by Piper Jaffray. As per Monday, June 26, the company rating was maintained by Jefferies. The rating was initiated by Brean Capital on Wednesday, October 21 with “Buy”. The firm has “Market Outperform” rating given on Friday, August 26 by JMP Securities. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Buy” rating given on Wednesday, September 2 by Piper Jaffray.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The company has market cap of $721.96 million. The Firm is focused on the development and commercialization of therapies to address unmet medical needs. It currently has negative earnings. The Company’s product portfolio includes HETLIOZ , Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Seekingalpha.com which released: “Vanda Pharmaceuticals Keeps Chugging Along” on June 26, 2017, also Prnewswire.com with their article: “Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 …” published on January 09, 2017, Prnewswire.com published: “Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on …” on July 17, 2017. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Seekingalpha.com and their article: “Vanda Pharmaceuticals’ (VNDA) CEO Mihael Polymeropoulos on Q4 2016 Results …” published on February 16, 2017 as well as Zacks.com‘s news article titled: “Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8% June 21, 2017” with publication date: June 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: